用几何深度学习设计能同时作用多个靶点的药物，突破传统单药单靶局限。

The traditional "one drug, one target" paradigm of structure-based drug design (SBDD) frequently proves inadequate for treating multifactorial diseases such as cancer and neurodegenerative disorders, owing to compensatory signaling pathways and the emergence of drug resistance. While polypharmacology offers a synergistic therapeutic strategy, the rational design of ligands capable of simultaneously satisfying the geometric constraints imposed by multiple targets remains a major computational bottleneck. This review positions geometric deep learning (GDL) as a powerful integrative approach to overcome these limitations. We systematically survey GDL architectures ranging from invariant graph neural networks to SE(3)-equivariant diffusion models that harness non-Euclidean molecular data to capture intrinsic three-dimensional (3D) structural interdependencies. We critically analyze GDL applications across three core dimensions, including the characterization of shared binding pockets via geometric embeddings, multi-target bioactivity prediction through heterogeneous graph fusion, and de novo generation of dual-target ligands. Particular emphasis is placed on emerging structure-conditioned generative algorithms that integrate diffusion models with reinforcement learning to autonomously resolve complex geometric conflicts between competing binding sites. Furthermore, we evaluate the pivotal role of multimodal omics integration and specialized geometric benchmarking infrastructures in validating these models. By synthesizing these methodological advances, this review elucidates the paradigm shift in drug discovery from serendipitous exploration to rational, structure-driven polypharmacological molecular engineering, thereby providing a clear, structured guide for navigating the complexities of next-generation therapeutics.